An Offensive Playbook

Developing nonaddictive drugs to combat pain

Written byMary Beth Aberlin
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

ANDRZEJ KRAUZEThe Super Bowl. Since the first kickoff in 1967, this event has become a consummate American ritual. Last year more than 108 million people tuned in. For at least a decade and a half, my family has attended the same neighborhood party: 15 lbs of kielbasa express-shipped from Buffalo, jambalaya, tubs of beer, congenial betting, ad rating via vocal voting. Everyone eats and emotes as the game unfolds on an enormous TV screen, where the players often seem larger than life.

The audible crunch of contact and the not-so-infrequent scenes of gigantic men writhing on the field in agony are poignant reminders that NFL football players suffer a lot of pain during their relatively short gridiron careers. To keep playing as long as possible, they down incredible amounts of painkillers, and many continue to take these medications long after retirement, not just because they are still suffering from football-acquired injuries, but because they are addicted, according to a 2010 study commissioned by ESPN and led by epidemiologist Linda Cottler while at Washington University in Saint Louis.

Unfortunately, NFL players are only a fraction of a very real and widespread problem: addiction to painkillers. In a feature article, “Pain and Progress,” Kerry Grens explains how opioid drugs ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies